First-in-human Study of 7MW4911 in GI Cancer
ConditionGI Cancers
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMabwell (Shanghai) Bioscience Co., Ltd.
About this trial
This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.
Eligibility criteria
Qualifiers
Aged 18 and above
ECOG 0-1
Life expectancy ≥ 3 months
Advanced or metastatic gastrointestinal cancer that has progressed after standard of care.
Disqualifiers
Other concurrent malignancy in the recent 3 years except for adequately treated carcinoma in situ.
Active, untreated or symptomatic CNS metastasis
Effusions that require frequent drainage
Patients with active autoimmune disease, except for type I diabetes, hypothyroidism and other autoimmune disease that does not require systemic treatment.
Trial design
Treatments tested in this trial
- 7MW4911
Treatment groups
200 Participants
are divided into 1 treatment groupLocations
5Hematology Oncology Associates of the Treasure Coast34952, Port Saint LucieFlorida, United States
Massachusetts General Hospital02114, BostonMassachusetts, United States
START11042, Long Island CityNew York, United States
START Moutain Region84119, West Valley CityUtah, United States
Sponsors and collaborators
Mabwell (Shanghai) Bioscience Co., Ltd.
Lead sponsor
Source ClinicalTrials.gov